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SUMMARY. A commercially available enzyme-immunometric assay for serum
a-glutathione S-transferase (GST) was evaluated. Endogenous serum a-GST diluted
linearly within the calibration range. However, we recommend that the sample and
second antibody reagent are always added sequentially in the assay to avoid hook
effect. Between-assay variability was below 70/0 across the calibration range and the
upper limit of the reference range in adults (n = 219) was II ·4 J.Lg/L. Within-individual
variability in serum a-GST concentrations measured over a 4-6 week period in 4
healthy adults was small. Serum a-GST concentrations did not change significantly
6 h after a therapeutic dose of paracetamol.
Studies in two patients after liver transplantation showed that serum
a-GST is a better discriminant of acute changes in liver function than conventional
tests. Serum a-GST concentrations were unaffected by gross muscle damage, extra-
hepatic inflammation, or haemolysis and thus appear to be more liver specific than
transaminase activities. The effect of renal impairment on serum a-GST concentrations
requires further investigation.
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The glutathione S-transferases (GSTs) (E.C.
2.5.1.18) form a complex family of enzymes,
primarily involved in the modification of
xenobiotics and some endogenous substrates
by catalysing their conjugation to reduced
glutathione. Some may also exhibit selenium-
independent glutathione peroxidase activity. 1,2 In
man, a-GST is found primarily within hepatocytes,
comprising approximately 5% of the total soluble
cytoplasmic protein mass, although it is also
present in the kidney, adrenal gland and testis.'
It is a dimeric protein made up of two subunits
(B1 and B2) and may exist as a homodimer (BIBj
and B2B2 ) or heterodimer (BIB2 ) . 2 A genetically
based nomenclature for GST has now been
proposed" distinguishing both the subunit
composition of individual isoenzyme as well
as allelic variants encoded at the same gene
locus (denoted by capital letters). In this new
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classification, the a-class dimers described
above are referred to as AI-I, A2-2 and AI-2,
respectively. However, since most published
research on GST has referred to BI and B2
subunits, the latter designation is followed in
this report.
The relatively small size of a-GST (mol.
wt == 50 (00) results in its rapid release following
hepatocellular damage. This property, together
with the restricted distribution of a-class GST in
tissues other than liver, the high concentration of
the enzyme within hepatocytes, its short plasma
half-life (approximately I h) and wide distribution
across the liver lobule should make a-GST
an ideal marker for monitoring acute changes in
hepatocellular integrity.! Monitoring a-GST has
been found to offer diagnostic and/or prognostic
advantages over conventional liver function tests
(LFfs) in a variety of acute clinical circum-
stances.t"! Serum a-GST concentrations also
appear to correlate better with the histopathological
575
 at PENNSYLVANIA STATE UNIV on September 17, 2016acb.sagepub.comDownloaded from 
576 Rees, Trull and Doyle
features of chronic conditions such as
chronic active hepatitis, even when conventional
transaminase activities are norma1. 14 - 16
Published methods for the measurement of
a-GST have usually been either non-specific and
susceptible to interference from endogenous
substances (enzymatic assays) or too time-
consuming.? However, a time-resolved immuno-
fluorometric assay has recently been described.'?
We have evaluated a commercial enzyme-




We used a commercially available enzyme-
immunometric assay for the quantitation of
serum a-GST (Biotrin International, Stillorgan,
Dublin, Ireland). Two procedures are described
by the manufacturers and these are outlined
below.
Sequential assay procedure
Stock calibration material was diluted in
phosphate buffered saline with 0·25% vlv
Tween 20 (assay buffer) to yield concentrations
in the range 1-50 ",giL. Serum samples and
quality control material were both diluted 1 in 5
in assay buffer. One hundred microlitres of
appropriately diluted calibrators, quality controls
and serum samples were added in duplicate to
microtitre plates pre-coated with affinity purified
polyclonal IgG antibody raised against purified
total hepatic a-GST (probably cross-reacting with
all a-GST dime ric forms). The assay plates were
incubated at 25°C for 1 h with shaking (DSG
Titretek plate shaker, speed 6). Then, the plate
was washed four times with 200 ",L assay buffer
and 100 ",L of the second antibody (polyclonal
anti-a-GST IgG conjugated to horseradish
peroxidase) resuspended in assay buffer was
added to each well. The plate was then incubated
for a further hour at 25°C with shaking. After
four further washes in assay buffer, 200 ",L of
liquid tetramethylbenzidine substrate was added
to each well and incubated for 10 min at 25°C
with shaking. The reaction was then stopped with
50 ",L I M sulphuric acid and the optical density
read at 450 nm (650 nm reference) on a Vmax
Kinetic Microplate Reader (NovoLabs). This
sequential assay procedure was adhered to for
all the studies described below unless stated
otherwise.
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Simultaneous assay procedure
Conditions were identical to the sequential assay
protocol except that the addition of second
antibody-HRP conjugate (100 ",L) followed
the addition of 100 ",L of appropriately diluted
serum samples, calibrators and quality control
material and the incubation time was 1 h. The
simultaneous assay procedure was only followed




A serum sample from a liver transplant recipient
with an a-GST concentration of about 3000 ",giL
was serially diluted and analysed by both
sequential and simultaneous assay procedures in
order to compare linearity.
Precision profile
Duplicate a-GST measurements on clinical
samples from 38 consecutive assays run on
different days over a 2 month period were used
to determine a precision profile across the
calibration range. Duplicate values were classified
into 12 concentration ranges (bins) and the bin
mean, standard deviation and coefficient of
variation calculated according to the method
of Raggatt.'!
Intra- and inter-assay variability
Alpha-GST was purified to homogeneity from
human liver as verified by SDS-PAGE and
isoelectric focusing. The absence of both "'- and
7I'"-GST was confirmed by Western blot analysis
of the purified protein. This purified hepatic
a-GST was added to a pool of normal human
serum to yield final concentrations of about 7·5,
25, 50 and 125",giL a-GST and assayed 28 times
in a single batch to assess intra-assay variability.
Inter-assay variability was determined by analysing
these samples in 24 consecutive assays (single kit
batch), run on different days over a period of one
month.
Reference range and biological
variability of a-GST
Blood samples were collected from 219 adult
blood donors (aged 18 to 65 years) in order to
determine the adult reference range. At least
15 sequential samples were collected at 09·00 am
in the morning from each of four healthy adult
volunteers over a period of between 34 and 42
days in order to provide a preliminary indication
of the biological variability.
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Blood samples were also collected from eight
healthy volunteers before and 6 h after the
ingestion of 1 g paracetamol in order to assess the
influence of a therapeutic dose on serum cx-GST
concentrations.
Tissue specificity studies
Serum samples were collected from patients with
a variety of clinical conditions in order to assess
the tissue specificity of changes in serum cx-GST.
Liver transplant recipients
Sequential serum samples were prospectively
collected from two liver allograft recipients to
compare the characteristic pattern of changes in
cx-GST and conventional LFTs seen during
hepatocellular damage associated with acute
allograft rejection following orthotopic liver
transplantation.
Patients with renal dysfunction
Serum samples from 33 patients with normal
liver function but elevated serum creatinine
concentrations (median 383 iLmollL; range 130 to
1364 iLmollL) were collected following routine
urea and electrolyte analysis.
Patient with rhabdomyolysis
Serial samples were collected from a patient with
clinically documented rhabdomyolysis and a peak
serum total creatinine kinase (CK) activity greater
than 400 times the upper limit of the reference
range.
Patients with rheumatoid arthritis
Serum samples were collected from 40 patients
with rheumatoid arthritis: 20 with raised serum
C-reactive protein (CRP) (median 31 mg/L; range
8-104 mg/L) and 20 with normal serum CRP
concentration « 6 mg/L). These were included
primarily to assess the influence of extra-hepatic
inflammatory disease on cx-GST measurements.
Many of these samples were also known to
contain high levels of IgM rheumatoid factor (up
to 1250 IU/mL) and, therefore, also served to
assess any influence of this potential source
of interference in the cx-GST immunoassay
(see below).
Interference studies
The influence of potential endogenous inter-
ferents on serum cx-GST measurements was
further investigated in a series of recovery
experiments.
Lipaemia
Intra-lipid was added to normal human serum to
give a triglyceride concentration of 63 mmollL.
Icterus
Five hundred microlitres, 100 mM NaOH
containing 30 giL bovine serum albumin was
saturated with unconjugated bilirubin (Sigma
Chemical Company). This was diluted 1/100 in
an aliquot of the serum pool to give a pool with
a bilirubin concentration of 591 iLmollL.
Haemolysis
Freshly donated whole blood was lysed by
repeated freeze-thawing giving a homogenous
lysate with a haemoglobin concentration of
15·2 g/dL.
The normal serum pool, icteric and lipaemic
serum pools and the whole blood haemosylate
was spiked to a target concentration of 100 iLg/L
purified human hepatic cx-GST. The three spiked
pools containing the potential interferents were
then mixed with the spiked normal serum pool
to yield the following proportions of interferent-
1000/0,80%,60%,40%,20%, 10%,5%,0%.
The recovery of spiked cx-GST in these serum
mixtures was then measured.
Paraproteins
In our earlier study of cx-GST in liver allograft
recipients.! samples from one patient with a low
concentration of serum IgM paraprotein appeared
to be a source of assay interference. This
interference was suspected from highly erratic
changes in daily cx-GSTmeasurements. This was
investigated by assessing the recovery of purified
cx-GSTadded to the patient's serum and to sera
from non-transplant patients with known serum
paraproteins of immunoglobulin classes IgG, IgA
or IgM. The latter were selected to provide a
broad range of paraprotein concentrations.
RESULTS
Assay pereformance
Figure 1 illustrates a marked 'hook effect'
associated with high cx-GST concentrations in the
simultaneous assay procedure-the maximum
absorbance occurring at a concentration of
approximately 60 iLg/L. By contrast, in the
sequential assay the optical density reached a
plateau at cx-GST concentrations above 100iLg/L.
In view of this finding, only the sequential
procedure was used in all other evaluations.
Ann Clin Biochem 1995: 32
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FIGURE I. Comparison of assay linearity for
simultaneous (n) and sequential (.) assay protocols.
GST= glutathione S-transferase.
FIGURE 2. Precision profile for the sequential assay
determined by the analysis of variabilitybetween sample
duplicates. Bin = concentration range; CV= coefficient
of variation.
The detection limit assessed as the mean plus
2· 5 times the standard deviation of eight a-GST
measurements of assay bufer alone was 0·5 p.g/L.
The precision profile is shown in Fig. 2. For
all a-GST concentrations within the range 0·2 to
50 p.g/L (equating with serum GST concentrations
of 1-250 p.g/L), the mean coefficient of variation
was less than 6070.
Table 1 shows the results of the precision study.
The inter-assay coefficient of variation (CV) only
exceeded 10% at a concentration of 7·5 p.g/L
(Table 1).
In all four healthy individuals monitored
sequentially, the median morning serum a-GST
concentration was 2 p.g/L (range 1-4 p.g/L). In the
longest series of 18 sequential samples, collected
from one individual over a period of 34 days, the
mean (SD) serum a-GST concentration was
2· 2(0' 4) p.g/L. There was no detectable pattern
within individuals.
Serum a-GST concentrations did not change
significantly 6 h after a therapeutic dose of
paracetamol (3' 5 ± 3 . 5 p.g/L pre-dose and
3· 2 ±2· 5 p.g/L post-dose).
Reference range and biological
variability of a-GST
Serum a-GST concentrations were log-normally
distributed and the upper limit of the reference
range (logarithmic mean + 2 SD) was 11. 4 p.g/L.
Tissue specificity and interference studies
The results of conventional LFTs and a-GST
measurements following liver transplantation in
two patients are shown in Fig. 3 (a,b). Both
patients experienced episodes of acute allograft
rejection within the first post-operative month.
TABLE I. Inter- (n =24) and intra-assay (n =28) variability for the sequential
assay protocol
Purified (Y-GST added to serum pool
Concentration of (Y-GST added
("giL) 7·5 25* 50 125
Measured (Y-GST concentration
Inter-assay
Mean 7·9 25·1 58·2 135·0
SD 1·1 1·4 3·5 6·4
CV (070) 14·2 5·5 6·1 4·8
Intra-assay
Mean 6·3 30·9 54·6 124·0
SD 0·2 1·0 1·2 5·8
CV (070) 2·9 3·1 2·2 4·7
·Two separate human serum pools were used to assess inter- and intra-assay
variability.
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early rejection episode on day 6. In this case,
a-GST concentration increased two days earlier
than conventional LFTs and 4 days prior to the
histological diagnosis of rejection. Unlike ALT,
serum a-GST fell rapidly to normal during
augmented immunosuppression. Serum a-GST
increased again on the thirteenth day, 1 day prior
to a rise in ALT and 3 days prior to recurrent
but apparently milder rejection. In the absence
of treatment, rejection persisted and a-GST
continued to increase in parallel with conventional
LFTs. Eventually, the mild/moderate rejection
appeared to resolve spontaneously without
treatment and there was a corresponding rapid
fall in a-GST and subsequent much slower fall
in ALT. The persistent increase in bilirubin and
ALP was compatible with the development of
early chronic rejection in this patient.
In patients with renal dysfunction but normal
conventional LFTs, no correlation was found
between serum creatinine and a-GST con-
centrations. Serum a-GST concentrations were
outside the reference range in two samples and
serum creatinine concentrations in these cases
were only marginally abnormal. The patient with
the highest serum a-GST was receiving digoxin
therapy but also had the highest serum ALT
activity of 48 IU/L (upper limit of reference
range 50 IU/L) in this group of patients. There
was no clinical explanation for the raised a-GST
concentration in the second patient.
Serial total CK and ALT activities as well
as a-GST concentrations in a patient with
rhabdomyolysis are shown in Fig. 4. Serum








FIGURE 3. Longitudinal changes in serum a-
glutathione S-transferase (GST, .), bilirubin (BILl,
0), alkaline phosphatase (ALP, ...) and alanine
transaminase (AL T, 0) measurements in two patients
(a and b) following orthotopic liver transplantation. All
results are expressed as multiples of the upper limit of
the respective reference range (broken line). (b) Biopsy
findings (arrowed): (I) moderate rejection (treated); (2)
mild rejection (no treatment); (3) mild/moderate
rejection plus necrosis; (4) resolved acute rejection.





FIGURE 4. Longitudinal changes in serum creatinine
kinase (CK, e), alanine transaminase (ALT, 0) and
a-glutathione s-transjerase (GST, .) measurements in
a patient with clinically diagnosed rhabdomyolysis.
In the first patient (a), all LFTs exceeded their
respective reference ranges in the immediate
post-operative period but only a-GST fell to
within the reference range by day 3. Subsequently,
there was a marked rise in a-GST as well as
alanine transaminase (AL T) and bilirubin. This
was associated with an episode of acute allograft
rejection diagnosed clinically on day 6 which
was successfully treated with the monoclonal
anti-T cell antibody OKT3. Consistent with the
resolution of rejection, a-GST concentrations fell
rapidly to within the reference range by the third
day of therapy and remained there throughout
the first post-operative month. Conventional
LFTs, however, failed to return to the reference
range during this time.
Similar biochemical changes were seen in the
second patient (Fig. 3b) in association with an
Ann C/in Biochem 1995: 32
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reference range, despite abnormal concentrations
of ALT. Aspartate transaminase (AST) "Y-
glutamyltransferase (GGT) activities measured on
the day of maximal CK activity (83300 U/L:
upper limit of reference range 195 U/L) were
found to be 2121 U/L (upper limit of reference
range 40 U/L) and 8 U/L (upper limit of
reference range 38 U/L), respectively. Serum
bilirubin and alkaline phosphatase measurements
remained within their reference ranges throughout
the patient's hospitalization.
Serum a-GST concentrations in rheumatoid
arthritis patients with a raised serum CRP were
not significantly different from either rheumatoid
arthritis patients with a low CRP or healthy
controls. However, four patients with a low CRP
had serum a-GST concentrations greater than
twice the upper limit of the reference range (27,
34, 42, and 83 JLg/L) and all had particularly high
IgM rheumatoid factor titres (214, 344, 1060, and
12501U/mL, respectively). Assay interference
was confirmed in the first and last of these
four samples, from the non-linear decrease in
measured a-GST concentration upon serum
dilution and from a 25 to 501170 over-recovery of
purified a-GST added to these samples. Serum
a-GST concentrations were significantly higher
in patients with rheumatoid factor tit res greater
than 70 lUlL (Fig. 5).
There appeared to be some under-recovery of
a-GST in the presence of bilirubin (mean recovery
94%; 95% confidence interval (CI) 89-99%).
However, there was no systematic increase in






Rheumatoid factor titre (IU/mL)
FIGURE 5. Serum a-glutathione S-transferase (GST)
concentrations in patients with rheumatoid arthritis
accordingto the titres ofserum rheumatoid factor (titres
below 70lUIL (n=15), 70 to 2JOIUIL (n=6) and
greater than 210 lUlL (n = 6)). Statistical differences
between groups were determined by Student's s-test.
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no significant interference by either lipaemia
(mean recovery 101%; 95% CI 98-104%) or
haemolysis (mean recovery 102%; 95% CI
99-105%).
Suspected assay interference by serum from a
liver transplant recipient with an IgM paraprotein
was confirmed by a 100 to 300% over-recovery
of purified a-GST added to the patient's serum
sample. However, eight further samples from
non-transplant patients with IgG (n = 4),
IgA (n = 1) and IgM (n = 3) paraproteins at
concentrations ranging from 10 to 64 giL did not
interfere in the measurement of a-GST.
DISCUSSION
We have evaluated a commercially available
enzyme immunometric assay for the quantitation
of total a-GST concentrations in human serum.
Most published methods for measuring a-GST
detect specific a-GST subunits whereas the
antiserum used here was raised against total
hepatic a-GST and, therefore, probably detects
all a-GST dimeric forms. The relative clinical
merits of measuring specific or total a-GST
subunits has not been established although the
use of antiserum that reacts with specific
a-GST subunits has been advocated because
the proportion of BIB2 heterodimer in liver
can vary markedly.s In a previous study we
have demonstrated the high sensitivity of the
immunometric assay for monitoring hepatocellular
integrity after human liver transplantation.!
However, that study did not assess the organ
specificity of serum total a-GST or involve any
technical validation of the assay.
We recommend that the sequential assay
protocol is followed since the simultaneous assay
procedure results in a marked high dose 'hook
effect' at serum a-GST concentrations greater
than 60 JLg/L (equivalent to 300 JLg/L in serum).
The upper limit of the reference range for
serum a-GST by this method was 11·4 JLg/L;
three to six times higher than that quoted for
methods that detect specific homodimers of the
enzyme (see Ref. 2). This probably reflects
the fact that the antiserum used in the current
method was raised against total hepatic a-GST.
Serial morning a-GST concentrations measured
over periods of 4-6 weeks in healthy adult
volunteers showed very little variation. Further
studies are warranted, however, to more fully
assess the biological variability in serum a-GST.
Such reproducibility is particularly important
when monitoring daily changes in liver function.
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Serum a-GST concentrations were unperturbed
6 h after a single therapeutic (1 g) dose of
paracetamol. The measurement of serum Q!-GST
at later time points after the dose will be necessary
to confirm this result but previous studies have
shown that patients who required treatment for
paracetamol overdose consistently had raised
serum Q!-GST as early as 4 h after the dose." One
of the potential applications of serum Q!-GST is
likely to be in the pharmaceutical industry to
monitor drug hepatotoxicity. However, it will be
necessary to examine the effect of repeated
therapeutic doses of paracetamol as well as other
commonly used potentially hepatotoxic drugs
on serum Q!-GST before this possibility can
be realized.
We followed two adult liver transplant recipients
longitudinally and a rise in Q!-GST was associated
with episodes of acute liver allograft rejection
confirming our previous observations.! In the
second case, persistent mild rejection appeared to
resolve spontaneously and Q!-GST concentrations
fell accordingly to normal-remaining within the
reference range despite the development of
chronic allograft dysfunction. Compatible with
the short in vivo half-life of Q!-GST (about 1 h),
we found that concentrations of the enzyme fell
more rapidly than conventional LFTs both
immediately after successful transplantation and
during resolution of rejection. This illustrates the
potential value of this test.
The relatively restricted distribution of the
enzyme in human tissues! could theoretically
offer advantages over conventional LFTs. Indeed,
serial measurements of Q!-GST were found to
remain persistently normal in a patient with
clinical rhabdomyolysis and serum creatine kinase
(CK) activities of up to 80000 U/L, accompanied
by markedly raised serum ALT and AST activities
despite the absence of any other clinical or
biochemical evidence of hepatocellular damage.
Numerous studies in both animals l9,2o and
humans21,22 suggest that such elevated serum
transaminase activities are due to release of
muscle isoforms from damaged fibres. Transient
hepatic dysfunction with elevated serum bilirubin
concentration and prolonged prothrombin time
has been reported in a series of patients with
non-traumatic rhabdornyolysis.P Under such
circumstances, where there is probably a true
dysfunction-a transient rise in serum Q!-GST
concentrations is likely.
Although immunohistochemical studies have
shown that Q!-GST is detectable in the normal
human kidney;' we found no relationship between
serum Q!-GST and creatinine concentrations:
Q!-GST concentrations were within the reference
range in 31 of 33 samples from patients with renal
dysfunction. There was no clinical explanation for
the abnormal serum Q!-GST measurements in the
two patients. The elevated enzyme levels could
be due to active kidney tissue damage. The patient
with the highest serum Q!-GST was receiving
digoxin therapy. The serum concentration of
digoxin, however, was not at concentrations likely
to cause acute nephrotoxicity. The detection of
increased Q!-GST concentrations in urine has been
reported to provide a measure of proximal
tubular damage in patients with raised serum
creatinine levels attributed to cyclosporin-induced
nephrotoxicity'" but this is not reflected in
increased serum concentrations. A more likely
explanation for the raised serum Q!-GST in this
case was perhaps mild occult liver disease as the
patient also had the highest serum ALT activity
of all 33 patients with renal failure.
The serum Q!-GST concentration in patients
with rheumatoid arthritis and a raised serum CRP
was not significantly different from that in
patients with a normal CRP or healthy blood
donors-confirming that Q!-GST is not a non-
specific marker of inflammation. However, this
study did alert us to a potentially important assay
interference. Raised serum concentrations of
Q!-GST were found in four patients and all four
of these patients had normal CRP but raised IgM
rheumatoid factor titres. In two cases, assay
interference was confirmed by over recovery
of added Q!-GST. It is well recognized that in
immunoassays IgM rheumatoid factor can give
rise to falsely elevated levels of analyte by binding
to the Fc portions of the capture and/or detection
antibodies.P-" Methods of sample pretreatment
to overcome this analytical problem have been
described,2R.29 but these are time-consuming.
Reduction of the capture antibody to its Fab
fragments" or use of avian capture/detection
antibodies" may be better options.
In our previous study we observed highly
erratic changes in daily Q!-GST measurements in
a transplant recipient" and assay interference
by serum was suspected. This interference was
confirmed from the over-recovery (> 1000J0)
of added Q!-GST. Interference was probably
attributable to the presence of low concentrations
(< 5 giL) of an IgM paraprotein in the serum-a
recognized potential source of interference in
imrnunoassays.P In eight samples from non-
transplant recipients with IgG, IgA and IgM
paraproteins, at concentrations up to 64 giL,
Ann Clin Biochem 1995: 32
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no interference in the a-GST immunoassay was
observed suggesting that this interference is rare.
Indeed, this was the only instance of interference
out of more than 4000 samples tested.
It is known that GSTs have a bilirubin binding
capacity which can interfere with activity
measurements of the enzyme in serum." It was,
therefore, necessary to exclude the possibility
that bilirubin may also affect the a-GST
immunoassay. This would be particularly relevant
in liver transplant recipients in whom serum
bilirubin levels may exceed 500 /Lmol/L. Although
there was a small (average 611,70) under-recovery
of a-GST spiked into icteric samples, there
was no evidence of concentration-dependent
interference by bilirubin at concentrations up to
591 /Lmol/L. It was also established that the assay
was not susceptible to interference by either
hyperlipidaemia or gross haemolysis.
In conclusion, monitoring serum a-GST offers
several clinical advantages over conventional
transaminase measurements as a marker of
hepatocellular damage. In particular, the enzyme
has a short in vivo half-life-allowing improved
discrimination of acute changes in liver function
over time. The test may also be more liver specific
than the transaminases. Although this immuno-
assay is not as rapid as those used for conventional
transaminase enzyme activity, it can be completed
within 2·25 h and assay precision is satisfactory
for routine daily monitoring.
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